Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):1015–1017. doi: 10.1038/bjc.1990.429

A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.

E E Vokes 1, R Mick 1, N J Vogelzang 1, R Geiser 1, F Douglas 1
PMCID: PMC1971562  PMID: 2257205

Full text

PDF
1015

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blachley J. D., Hill J. B. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med. 1981 Nov;95(5):628–632. doi: 10.7326/0003-4819-95-5-628. [DOI] [PubMed] [Google Scholar]
  2. Buckley J. E., Clark V. L., Meyer T. J., Pearlman N. W. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med. 1984 Dec;144(12):2347–2348. [PubMed] [Google Scholar]
  3. Dentino M., Luft F. C., Yum M. N., Williams S. D., Einhorn L. H. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978 Apr;41(4):1274–1281. doi: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  4. Lam M., Adelstein D. J. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis. 1986 Sep;8(3):164–169. doi: 10.1016/s0272-6386(86)80020-8. [DOI] [PubMed] [Google Scholar]
  5. Loehrer P. J., Einhorn L. H. Drugs five years later. Cisplatin. Ann Intern Med. 1984 May;100(5):704–713. doi: 10.7326/0003-4819-100-5-704. [DOI] [PubMed] [Google Scholar]
  6. Safirstein R., Winston J., Goldstein M., Moel D., Dikman S., Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Dis. 1986 Nov;8(5):356–367. doi: 10.1016/s0272-6386(86)80111-1. [DOI] [PubMed] [Google Scholar]
  7. Schilsky R. L., Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun;90(6):929–931. doi: 10.7326/0003-4819-90-6-929. [DOI] [PubMed] [Google Scholar]
  8. Schilsky R. L., Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun;90(6):929–931. doi: 10.7326/0003-4819-90-6-929. [DOI] [PubMed] [Google Scholar]
  9. Schilsky R. L., Barlock A., Ozols R. F. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep;66(9):1767–1769. [PubMed] [Google Scholar]
  10. Stewart A. F., Keating T., Schwartz P. E. Magnesium homeostasis following chemotherapy with cisplatin: a prospective study. Am J Obstet Gynecol. 1985 Nov 15;153(6):660–665. doi: 10.1016/s0002-9378(85)80255-6. [DOI] [PubMed] [Google Scholar]
  11. VALLEE B. L., WACKER W. E., ULMER D. D. The magnesium-deficiency tetany syndrome in man. N Engl J Med. 1960 Jan 28;262:155–161. doi: 10.1056/NEJM196001282620401. [DOI] [PubMed] [Google Scholar]
  12. Vogelzang N. J., Torkelson J. L., Kennedy B. J. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985 Dec 15;56(12):2765–2770. doi: 10.1002/1097-0142(19851215)56:12<2765::aid-cncr2820561208>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  13. Vokes E. E., Moran W. J., Mick R., Weichselbaum R. R., Panje W. R. Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol. 1989 Jul;7(7):838–845. doi: 10.1200/JCO.1989.7.7.838. [DOI] [PubMed] [Google Scholar]
  14. Vokes E. E., Panje W. R., Mick R., Kozloff M. F., Moran W. J., Sutton H. G., Goldman M. D., Tybor A. G., Weichselbaum R. R. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15;66(2):206–213. doi: 10.1002/1097-0142(19900715)66:2<206::aid-cncr2820660203>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. Von Hoff D. D., Schilsky R., Reichert C. M., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527–1531. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES